AnaptysBio ends alopecia areata trial; launches Phase 2b for RA and atopic dermatitis

ANAPTYSBIO, INC

Rosnilimab Phase 2a in alopecia areata failed to achieve target efficacy (no patient SALT<20); further development discontinued.
Advancing rosnilimab (PD-1 agonist) into global Phase 2b for rheumatoid arthritis; initiates Q3 2023, top-line mid-2025.
Advancing ANB032 (BTLA agonist) into global Phase 2b for atopic dermatitis; initiates Q2 2023, top-line year-end 2024.
Cash and investments >$575M as of Dec 31, 2022; estimated ~4-year runway excluding GSK royalties.
Rosnilimab second Phase 2 trial in undisclosed indication expected by year-end 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.